Radiation treatment of the heart versus repeat catheter ablation for ventricular tachycardia
Compares cardiac radioablation with repeat catheter ablation in people whose ventricular tachycardia returned.
Key facts
- Who runs it
- Varian, a Siemens Healthineers Company
- Where
- Boston, Charleston, Columbia, Columbus, Hartford, Los Angeles, Nashville, New Haven, Philadelphia, Pittsburgh, Rochester, and St Louis, United StatesSee the 12 sites
- Trial code
- Registry title
- Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
- Status
- Recruiting
- People taking part
- 380 people, planned
- Started
- 21 Apr 2023
- Expected to end
- May 2032
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Varian Cardiac Radioablation (CRA)
- Catheter Ablation (CA)
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high-risk ventricular tachycardia (a fast, dangerous heart rhythm) that came back after catheter ablation. It compares cardiac radioablation with a repeat catheter ablation.
- Age
- 18 years or older (or the local age of adulthood).
- Sex
- All sexes can join.
- Disease stage
- Ischemic and/or nonischemic cardiomyopathy with recurrent sustained monomorphic VT in the prior 6 months, after the last ablation. LVEF (heart pumping strength) must be ≤49%. The doctor must judge that a repeat catheter ablation is needed and possible. People must have an ICD (implanted defibrillator).
- Earlier treatment
- At least one prior catheter ablation for VT. Amiodarone must have failed (VT while taking it, minimum cumulative dose of 10 g) or caused side effects that made people stop it.
Main reasons for not taking part
- Any prior radiation to the chest area.
- Having an LVAD (heart pump), or being scheduled for an LVAD or heart transplant.
- VT ablation in the prior 2 weeks, or current use of inotropes (drugs that boost heart pumping).
- Polymorphic VT or ventricular fibrillation as the main rhythm, bundle branch reentry VT, or unstable non-stop VT.
- Being pregnant or breastfeeding, or an illness likely to limit survival to < 1 year.
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- High-risk refractory VT, defined as:; Ischemic and/or nonischemic cardiomyopathy, and; Recurrent sustained monomorphic VT, defined as at least one of the following below, documented by ICD interrogation or ECG in the prior 6 months, and having occurred after the last VT ablation:; A: ≥3 episodes of monomorphic VT treated with anti-tachycardia pacing (ATP) at least one of which is symptomatic; B: ≥1 appropriate ICD shock; C: ≥3 episodes of sustained monomorphic VT within 24 hours treated with ICD shock or ATP; D: sustained monomorphic VT below detection rate of ICD documented by ECG, and; Left ventricular ejection fraction (LVEF) ≤49% and; Previously underwent at least one standard of care CA for VT
- Presence of a clinical indication for a repeat CA procedure for scar-mediated VT in the judgement of the treating investigator
- Has failed amiodarone therapy or is intolerant to amiodarone:; Failed amiodarone therapy is defined as: appropriate ICD therapy or sustained monomorphic VT having occurred while the patient was taking amiodarone (minimum cumulative dose of 10 g); Intolerant to amiodarone is defined as: previously tried or taken amiodarone but stopped due to medication related side effects or toxicities
- Deemed to be medically and technically a candidate for further CA by the electrophysiologist investigator
- Presence of an ICD
- At least 18 years of age (or meets local age of majority)
- Ability to understand and willingness to sign an IRB approved written informed consent document
Who cannot take part
- Any prior radiation to the thorax region of the body
- VT ablation procedure performed within the prior 2 weeks
- >3 distinct clinical monomorphic VT morphologies on ICD interrogation since the prior CA, or >5 induced monomorphic VT morphologies during NIPS testing
- Patients of childbearing potential who:; are not on a medically effective means of birth control at the time of screening or do not start a medically effective means of birth control prior to randomization; or; do not agree to continue medically effective means of birth control until they have completed their assigned therapy; or; do not agree to be on a medically effective means of birth control if they are treated with CRA after their index CA procedure
- Contraindication to a CA procedure for VT (e.g., presence of mobile LV thrombus, active systemic infection, active ischemic or other reversible causes of VT)
- Known medical conditions associated with higher risk of radiotherapy complications in the judgement of the radiation oncologist (i.e., active connective tissue disorders, interstitial lung disease, etc.) that would preclude safe delivery of CRA
- Scheduled for LVAD or heart transplant procedures
- Presence of a systemic illness likely to limit survival to < 1 year
- Polymorphic VT or ventricular fibrillation (VF) as the primary clinical heart rhythm, as indicated by 12-lead ECG and/or ICD interrogation
- Patients enrolled or planned to be enrolled in another cardiac radioablation clinical study or registry
- Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation
- Patients with expected, right ventricular scar only
- Current use of inotropes
- Presence of a left-ventricular assist device (LVAD)
- Incessant VT that is hemodynamically unstable
- Bundle branch reentry (BBR) VT
- Pregnant and/or breastfeeding. (Patient denial is sufficient for enrollment)
- Patients enrolled in another clinical study the investigator believes to be in conflict with this clinical investigation
Where in United States
- Brigham & Women's HospitalBoston, United StatesContact: Christine PellegriniTaking people
- Medical University of South CarolinaCharleston, United StatesContact: Jeffrey Winterfield, MD (principal investigator)Taking people
- University of MissouriColumbia, United StatesContact: Nadine KallasTaking people
- The Ohio State UniversityColumbus, United StatesContact: Adrianne MillerTaking people
- Hartford HospitalHartford, United StatesContact: Megan ScalzoTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Kelsey DugginTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Terry WeyandTaking people
- Yale UniversityNew Haven, United StatesContact: Margaret Leiss, RNTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Karen TangTaking people
- University of Pittsburgh Medical CenterPittsburgh, United StatesContact: Eric PasquantonioTaking people
- Mayo ClinicRochester, United StatesContact: Brian LiddellTaking people
- Washington UniversitySt Louis, United StatesContact: Kaitlin MooreTaking people
About the trial
What the trial wants to find out
RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.
The 2 groups in the trial
- Repeat catheter ablation (CA)Existing treatment, for comparison
Treatment: Catheter Ablation (CA)
- Varian Cardiac Radioablation (CRA)Treatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia
- Plain-language title
- Radiation treatment of the heart versus repeat catheter ablation for ventricular tachycardiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 30 October 2026